Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research

International Journal of Methods in Psychiatric Research

Volumn 23, Issue S1, 2014, Pages 92-101

  Fava, Giovanni A ^a   Tossani, Eliana ^a   Bech, Per ^b,c   Berrocal, Carmen ^d   Chouinard, Guy ^e   Csillag, Claudio ^b,c   Wittchen, Hans Ulrich ^f   Rief, Winfried ^g  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Psychiatric Research Unit   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF MÁLAGA   (Spain)

^e université Paris Diderot Paris 7   (France)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clinical trials; Comorbidity; Iatrogenic disturbances; Illness behaviour; Mental disorder; Psychological well being

Indexed keywords

CLINICAL TRIAL (TOPIC); COMORBIDITY; HUMAN; MEDICAL RESEARCH; MENTAL DISORDERS; PROCEDURES; PSYCHOLOGY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; MENTAL DISORDERS;

EID: 84891057668     PISSN: 10498931     EISSN: 15570657     Source Type: Journal    
DOI: 10.1002/mpr.1412     Document Type: Article

References (59)

1. American Psychiatric Association (APA). (1980) Diagnostic and Statistical Manual of Mental Disorders: DSM-III, Washington, DC, American Psychiatric Publishing.
2. American Psychiatric Association (APA). (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, Washington, DC, American Psychiatric Publishing.
3. Andrews G. (1996) Comorbidity and the general neurotic syndrome. British Journal of Psychiatry, l68(Suppl. 30), 76-84.
4. Bech P. (2010) Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychotherapy and Psychosomatics, 79(6), 331-338.
5. Bech P. (2012) Clinical psychometrics, Oxford, Wiley-Blackwell.
6. Beesdo K., Bittner A., Pine D.S., Stein M.B., Höfler M., Lieb R., Wittchen H.-U. (2007) Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Archives in General Psychiatry, 64(8), 903-912.
7. Belaise C., Gatti A., Chouinard V.A., Chouinard G. (2012) Patient online report of selective serotonin reuptake inhibitor-induced persistent post-withdrawal anxiety and mood disorders. Psychotherapy and Psychosomatics, 81(6), 386-388.
8. Benedetti A., Pini S., de Girolamo G., Berrocal C., Tundo A., Morosini P., Cassano G.A. (2009) The psychotic spectrum: a community-based study. World Psychiatry, 8(2), 110-114.
9. Berk M., Ng F., Dodd S., Goldberg J.F., Malhi, G.S. (2010) Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. Psychiatry and Clinical Neurosciences, 64(4), 367-371.
10. Berrocal C., Pennato T., Bernini O. (2009) Relating coping, fear of uncertainty and alexithymia with psychological distress: the mediating role of experiential avoidance. Journal of Cognitive-Behavioral Psychotherapy, 9(2), 149-159.
11. Bittner A., Goodwin R.D., Wittchen H.-U., Beesdo K., Höfler M., Lieb R. (2004) What characteristics of primary anxiety disorders predict subsequent major depression? Journal of Clinical Psychiatry, 65(5), 618-626.
12. Boyd J.H., Burke Jr J.D., Gruenberg E., Holzer C.E., Rae D.S., George L.K., Karno M., Stoltzman R., McEvoy L., Nestadt G. (1984) Exclusion criteria of DSM-III: a study of co-occurrence of hierarchy-free syndromes. Archives of General Psychiatry, 41(10), 983-989.
13. Burke Jr J.D., Wittchen H.U., Regier D.A., Sartorius N. (1990) Extracting information from diagnostic interviews on co-occurrence of symptoms of anxiety and depression. In Maser J.D., Cloninger C.R. (eds) Comorbidity of Mood and Anxiety Disorders, pp. 649-667, Washington, DC, American Psychiatric Press.
14. Chouinard G., Chouinard V.A. (2008) Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics, 77(2), 69-77.
15. Chouinard G., Jones B.D., Annable L. (1978) Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry, 135(11), 1409-1410.
16. Chouinard G., Labonte A., Fontaine R., Annable L. (1983) New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 7(4), 669-673.
17. Cloninger C.R., Martin R.L., Guze S.B., Clayton P.J. (1990) The empirical structure of psychiatric comorbidity and its theoretical significance. In Maser J.D., Cloninger C.R. (eds) Comorbidity of Mood and Anxiety Disorders, pp. 439-462, Washington, DC, American Psychiatric Press.
18. Cosci F., Fava G.A. (2013) Staging of mental disorders: systematic review. Psychotherapy and Psychosomatics, 82(1), 20-34.
19. de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. (2003) How to measure comorbidity: a critical review of available methods. Journal of Clinical Epidemiology, 56(3), 221-229.
20. Emmelkamp P.M., Bouman T.K., Blaauw E. (1994) Individualized versus standardized therapy: a comparative evaluation with obsessive-compulsive patients. Clinical Psychology and Psychotherapy, 1(2), 95-100.
21. Emmrich A., Beesdo-Baum K., Gloster A.T., Knappe S., Höfler M., Arolt V., Deckert J., Gerlach A.L., Hamm A., Kircher T., Lang T., Richter J., Ströhle A., Zwanzger P., Wittchen, H.-U. (2012) Depression does not affect the treatment outcome of CBT for panic and agoraphobia: results from a multicenter randomized trial. Psychotherapy and Psychosomatics, 81(3), 161-172.
22. Enck P., Bingel U., Schedlowski M., Rief W. (2013) The placebo response in medicine: minimize, maximize or personalize? Nature Reviews Drug Discovery, 12(3), 191-204.
23. Fava G.A., Offidani E. (2011) The mechanisms of tolerance in antidepressant action. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(7), 1593-1602.
24. Fava G.A., Rafanelli C., Tomba E. (2012a) The clinical process in psychiatry: a clinimetric approach. Journal of Clinical Psychiatry, 73(2), 177-184.
25. Fava G.A., Sonino N., Wise T.N. (2012b) The psychosomatic assessment: strategies to improve clinical practice, Basel, Karger.
26. Fava G.A., Tomba E., Tossani E. (2013) Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 40, 306-311.
27. Feinstein A.R. (1970) The pre-therapeutic classification of comorbidity in chronic disease. Journal of Chronic Diseases, 23, 455-468.
28. Ferrari R., Russell A.S. (2010) Correlations between coping styles and symptom expectation for rheumatoid arthritis. Clinical Rheumatology, 29(12), 1445-1448.
29. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. (1996) User's Guide for the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II), Washington, DC, American Psychiatric Press.
30. First M.B., Spitzer R.L., Willams J.B.W. (1990) Exclusionary principles and the comorbidity of psychiatric diagnoses: a historical review and implications for the future. In Maser J.D., Cloninger C.R. (eds) Comorbidity of mood and anxiety disorders, pp. 83-109, Washington, DC, American Psychiatric Press.
31. Frances A.J., Widiger T.A., Fyer M.R. (1990) The influence of classification methods on comorbidity. In Maser J.D., Cloninger C.R. (eds) Comorbidity of Mood and Anxiety Disorders, pp. 41-59, Washington, DC, American Psychiatric Press.
32. Holma I.A.K., Holma K.M., Melartin T.K., Rytsälä H.J., Isometsä E.T. (2012) A 5-year prospective study of predictors for disability pension among patients with major depressive disorder. Acta Psychiatrica Scandinavica, 125(4), 325-334.
33. Kales A., Scharf M.B., Kales J.D. (1978) Rebound insomnia: a new clinical syndrome. Science, 201(4360), 1039-1041.
34. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry, 51(1), 8-9.
35. Klerman G.L. (1990) Approaches to the phenomena of comorbidity. In Maser J.D., Cloninger C.R. (eds) Comorbidity of mood and anxiety disorders, pp. 13-37, Washington, DC, American Psychiatric Press.
36. Knappe S., Hoyer J. (in press) Clinical assessment of anxiety disorders. In Emmelkamp P.M.G., Ehring T. (eds) The Wiley handbook of anxiety disorders. Chichester, Blackwell-Wiley.
37. Kroenke K. (2003) The interface between physical and psychological symptoms. The Primary Care Companion to the Journal of Clinical Psychiatry, 5(Suppl. 7), 11-18.
38. Lin C.H., Lane H.Y., Chen C.C., Juo S.H.H., Yen, C.F. (2011) Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder. Clinical Journal of Pain, 27(9), 805-810.
39. Lincoln T.M., Lüllmann E., Rief W. (2007) Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophrenia Bulletin, 33(6), 1324-1342.
40. Maser J.D., Cloninger C.R. (eds). (1990) Comorbidity in anxiety and mood disorders, Washington, DC, American Psychiatric Press.
41. Merikangas K.R., Angst J., Eaton W.Y.C., Canino G.R.S.M. (1996) Comorbidity and boundaries of affective disorders with anxiety disorders and substance misuse: results of an international task force. British Journal of Psychiatry, 168(Suppl. 30), 58-67.
42. Otto M.W., Nierenberg A.A. (2002) Assay sensitivity, failed clinical trials, and the conduct of science. Psychotherapy and Psychosomatics, 71(5), 241-243.
43. Rief W., Mewes R., Martin A., Glaesmer H., Braehler E. (2010) Are psychological features useful in classifying patients with somatic symptoms? Psychosomatic Medicine, 72(7), 648-655.
44. Rief W., Nestoriuc Y., Weiss S., Welzel E., Barsky A.J., Hofmann S.G. (2009) Meta-analysis of the placebo response in antidepressant trials. Journal of Affective Disorders, 118(1), 1-8.
45. Schumann G., Binder E., Holte A., de Kloet E.R., Odegaard K.J., Robbins T.W., Walker-Tilley T.R., Brown V.J., Buitelaar J., Ciccocioppo R., Cools R., Escera C., Fleischhacker W., Flor H., Frith C.D., Heinz A., Johnsen E., Kirschbaum C., Klingberg T., Lesch K.-P., Lewis S., Maier W., Mann K., Martinot J.-L., Meyer-Lindenberg A., Müller C.-P., Müller W.-E., Nutt D.-J., Persico A., Perugi G., Pessiglione M., Preuss U.W., Roiser J., Rossini P.M., Rybakowski J.K., Sandi C., Stephan K.E., Undurraga J., Vieta E., van der Wee N., Wykes T., Haro J.M., Wittchen H.-U. (2013) Stratified medicine for mental disorders. European Neuropsychopharmacology. DOI 10.1016/j.euroneuro.2013.09.010 e-pub ahead of print.
46. Spitzer R.L., Endicott J., Robins E. (1978) Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry, 35(6), 773-782.
47. Stein M.B., Fuetsch M., Müller N., Höfler M., Lieb R., Wittchen H.-U. (2001) Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Archives of General Psychiatry, 58(3), 251-256.
48. Tinetti M.E., Fried T. (2004) The end of the disease era. American Journal of Medicine, 116(3), 179-185.
49. Tomba E. (2012) Nowhere patients. Psychotherapy and Psychosomatics, 81(2), 69-72.
50. Tomba E., Bech P. (2012) Clinimetrics and clinical psychometrics: macro- and micro-analysis. Psychotherapy and Psychosomatics, 81(6), 333-343.
51. Tossani, E. (2013) The concept of mental pain. Psychotherapy and Psychosomatics, 82(2), 67-73.
52. Verboom C.E., Sentse M., Sijtsema J.J., Nolen W.A., Ormel J., Penninx B.W.J.H. (2011) Explaining heterogeneity in disability with major depressive disorder: effects of personal and environmental characteristics. Journal of Affective Disorders, 132(1), 71-81.
53. Weissman M.M., Bland R.C., Canino G.J., Faravelli C., Greenwald S., Hwu H.G., Joyce P.R., Karam E.G., Lee C.K., Lellouch J., Lépine J.P., Newman S.C., Rubio-Stipec M., Wells J.E., Wickramaratne P.J., Wittchen H.U., Yeh E.K. (1996) Cross-national epidemiology of major depression and bipolar disorder. JAMA: The Journal of the American Medical Association, 276(4), 293-299.
54. Wittchen H.U. (1996a) What is comorbidity-fact or artefact? British Journal of Psychiatry, 168(30), 7-8.
55. Wittchen H.U. (1996b) Critical issues in the evaluation of comorbidity of psychiatric disorders. British Journal of Psychiatry, 168(Suppl. 30), 9-16.
56. Wittchen H.-U., Pfister H. (1997) DIA-X-Interviews: Manual für Screening Verfahren und Interview; (DIA-X-Lifetime); Ergänzungsheft (DIA-X-Lifetime); Interviewheft Querschnittsuntersuchung (DIA-X-12 Monate); Ergänzungsheft (DIA-X-12 Monate); PC-Programm zur Durchführung des Interviews (Längs- und Querschnittsuntersuchung); Auswertungsprogramm, Frankfurt, Swets & Zeitlinger
57. World Health Organization (WHO). (1990) Composite International Diagnostic Interview (CIDI), Version 1.0, Geneva, WHO.
58. World Health Organization (WHO). (1992) The ICD-10 Classification of Mental and Behavioural Disorders: Clinical description and diagnostic guidelines, Geneva, WHO.
59. Zimmerman M., Chelminski I., McDermut W. (2002) Major depressive disorder and axis I diagnostic comorbidity. Journal of Clinical Psychiatry, 63(3), 187-193.